CanadaTorontoNorth America
Connecting Innovation.Advancing Healthcare.Building the Future.
Nexara Pharma is a global healthcare and life sciences company delivering quality products, medical technologies and innovative solutions today — and building pharmaceutical manufacturing capacity for tomorrow.
Building Pharmaceutical Manufacturing Capacity in Afghanistan
Planned
Global Presence8 Countries
PartnershipsInternational Network
Product PortfolioWide RangeTherapeutic areas
Future ManufacturingPlanned in Afghanistan
About Nexara
A Global Healthcare and Life Sciences Company
Nexara Pharma is built on trust, quality and long-term relationships. We meet emerging healthcare needs across medicines, medical technologies, digital health, supplements, raw materials and international partnerships — while developing pharmaceutical manufacturing capacity in Afghanistan for the longer term.
Our Vision
Healthier lives and stronger communities worldwide.
Our Mission
Deliver quality healthcare through innovation and partnership.
Our Values
Quality, integrity, innovation and compassion.
Our Commitment
Improving outcomes through responsible growth.
Our Model
Two Engines, One Direction
Nexara is built as two connected engines: a near-term trading, OEM/ODM and distribution business, and a long-term Afghanistan manufacturing investment. The first builds supplier relationships, market intelligence and regulatory knowledge. The second follows once that foundation — and verified demand — is in place.
Pillar 1 — Trading today
OEM, Private Label & Distribution
Global sourcing of medical devices, diagnostics, smart ring technology and Japanese supplements, moved under private-label, OEM and ODM terms into Central Asia, South Asia, the Gulf and North America.
Pillar 2 — Manufacturing tomorrow
The Afghanistan Complex
An integrated, GMP-oriented manufacturing complex — a separate, asset-backed investment stream that draws on the market intelligence the trading business builds first.
Global Presence
A Global Network, Working for Better Health
CanadaTorontoNorth America
UAEDubaiMiddle East Hub
JapanYokohamaInnovation & Tech
AfghanistanKabulOperations Hub
PakistanPeshawarMarket Development
UzbekistanTashkentCentral Asia
IndiaThanePharma Partnerships
ChinaHefeiSupply & Manufacturing
Eight offices. Our own people.
These are offices Nexara staffs, not agents. Every entry below carries the real address.
India
Thane
201, Centura Square IT Park, SG Barve Rd, Shree Nagar, Thane West, Maharashtra 400604
Telephone to follow
China
Hefei
Intersection of Liaoning Road and Huanghe Road, Hefei City, Anhui Province
Telephone to follow
Pakistan
Peshawar
Office 106, Second Floor, Mohmand Plaza, Namak Mandi, Peshawar City, KPK
Telephone to follow
Uzbekistan
Tashkent
Room 507, NEUS Business Center, 76 Arnasoy Street, Chilanzar District, Tashkent
Our Healthcare Solutions
Comprehensive Portfolio. Better Outcomes.
PharmaceuticalsQuality medicines across major therapeutic areas.
Oncology & Specialty CareAdvanced therapies for complex conditions.
Medical Devices & DiagnosticsDevices and diagnostics for faster decisions.
Digital Health & WearablesSmart technologies for monitoring health.
Nutraceuticals & SupplementsJapanese evidence-based supplements.
APIs & IngredientsAPIs and excipients from trusted manufacturers.
Laboratory SolutionsLab chemicals, reagents, standards and equipment.
Veterinary & Animal HealthQuality solutions for animal health.
Medical EquipmentHospital equipment and consumables.
OEM / ODM & Private LabelCustom development and private label.
Registration status. Availability of any product depends on registration
and market authorisation in each territory. Nothing here should be read as a statement that
a product is approved or commercially available in your market.
Innovation & Digital Health
Healthcare Meets Technology
Nexara distributes the FyRing range of connected-health wearables in partnership with MedVigilance, alongside the diagnostic and monitoring lines that sit in the same programme.
An animated three-dimensional representation of a smart ring.
Continuous monitoringWorn devices that capture data continuously rather than at single points of care.
Connected dashboardsDevice data surfaced to the individual and, where a programme allows it, to the institution running it.
Market-by-market classificationWearables carry different regulatory classifications by territory. Nexara confirms the position before supply.
Technical specificationsDetailed specifications are shared with qualified partners rather than published on this page.
Illustration, not a product image. The rotating ring above is an abstract
representation of the wearable category. Photographs of the actual FyRing devices appear in
the product section below.
Portfolio
Products We Carry
Every line names its manufacturer. If we cannot name who made it, we do not carry it.
The King Agaricus KA21 Line
Manufactured by Toei Shinyaku Co., Ltd. in Japan from a single cultivated Agaricus blazei strain, KA21. Working from one strain is what lets a single specification hold across the range.
View details
King Agaricus 100 — SachetsLiquid extract in single-serve sachets. The flagship presentation.
View details
King Agaricus 100 — TabletsThe same extract in tablet form, for markets preferring a solid dose.
View details
BEROOTKA21 combined with beetroot extract, in the everyday range.
View details
NKUP for MenA men's formulation built on the KA21 base extract.
View details
CleansiaA daily formulation from the same manufacturer and base.
View details
King Agaricus 100 for PetsA veterinary presentation for companion animals.
View details
KA21 Raw MaterialBulk extract for formulators and contract manufacturers.
View details
The KA21 StrainCultivated in Japan under controlled conditions.
Smart Rings & Wearables
FyRing 2 and FyRing SE, manufactured by MedVigilance Inc., Japan.
View details
FyRing 2Titanium body, continuous optical sensing, 1-lead ECG, IP68 water resistance and Bluetooth Low Energy 5.0. Battery of five to seven days.
View details
FyRing SECeramic outer case, optical sensing, IP68 and BLE 5.0. Black plus fourteen customisable colourways.
Selected models feed a business healthcare dashboard rather than a single consumer app — sleep scoring, whole-cohort health status on one screen, and secure sharing across a family group or managed programme. Raw accelerometer and PPG data are exportable.
Point-of-Care Diagnostics
Eight device families supplied on private-label, OEM and ODM terms.
Blood Glucose
Meters, strips and lancing systems for diabetes management.
Multi-Function Analysers
Combined platforms measuring several markers from one sample.
Uric Acid
Rapid quantitative testing for gout and metabolic screening.
Lipid Panel
Cholesterol, HDL, LDL and triglycerides at the point of care.
Haemoglobin
Anaemia screening for clinics, blood drives and field programmes.
Urine Analysis
Multi-parameter strips and readers for routine urinalysis.
Fertility
Ovulation and pregnancy rapid tests in cassette, strip and midstream.
Infectious Disease
Rapid antigen and antibody tests across a range of pathogens.
Registration and claims vary by market. Device availability and approved
indications differ by jurisdiction, and registration status is confirmed per market before
any commitment. The King Agaricus KA21 line is sold as a food supplement, not a medicine,
and is labelled accordingly in every market.
Advisory & Leadership
Guided by Expertise. Driven by Purpose.
Nexara is directed by a Founder's Office and supported by international advisory, medical and scientific councils, executive leadership and country teams.
Titles carried over from Nexara's existing site. These are the names and
titles Nexara already publishes, not titles I have written. The corporate profile still
marks leadership entries "subject to individual review and approval", so please confirm each
one before this page goes live. Biographies and quotations are not published here yet.
Jalaluddin Saeed
Founder & Chairman
Saduddin Saeed
Co-Founder & Vice Chairman
Dr. Mohammad Humayon Qayoumi
Chairman, International Advisory Board
Ustad Rahimullah
Chairman — International Investment, Infrastructure & Strategic Development Council
Professor Dr. Abdul Matin Jalalzai
President, Medical & Scientific Advisory Council
Dr. Fazal Zakaria Mujaddidi
Director, Advisory Board of Surgery | Strategic Partner | Professor of General Surgery
Jeffrey Grieco
Chairman — U.S. Government Relations, International Trade & Strategic Partnerships Council
Satoshi Geng
Partner & Chief Executive Officer — Japan Market | Global Director — Digital Health Innovation & Smart Technologies
Ajmal Bashir
President — UAE & Middle East
Ehsan Malik
Partner & Chief Executive Officer — Pakistan Market
Manufacturing Vision
Building Pharmaceutical Manufacturing Capacity in Afghanistan
A long-term, GMP-oriented manufacturing concept, subject to feasibility, engineering, regulatory approvals, financing, qualified technical partners and phased investment.
This facility does not yet exist. Nexara does not currently operate a
pharmaceutical manufacturing facility in Afghanistan. Everything in this section describes
a planned and proposed future vision. No image on this website depicts an existing
Nexara factory.
The five-year roadmap
Trade first. Manufacture once it is proven. The plan moves step by step, building distribution strength before investing in production.
2019 · Complete
AID Group Established
The industrial base — agriculture, processing, logistics and lab services — that Nexara is built on.
2023 · Complete
Build & Establish
Canadian office opens in Abbotsford. Supplier qualification, initial products and regulatory mapping begin.
2024 · Complete
Expand & Strengthen
Supply agreements signed with Toei Shinyaku for KA21 and MedVigilance for smart ring technology.
2026–2027 · In progress
Establish & Integrate
Eight offices live across eight countries. Governance strengthened and first market channels opened.
2027–2028 · Planned
Expand & Register
Broader portfolio, private-label projects and country-by-country product registration.
2028–2029 · Planned
Prepare Manufacturing
Feasibility completed, facility design fixed, technical partners appointed and capital staged.
2029–2031 · Planned
Build & Validate
Facility development, equipment installation, technical recruitment and systems validation.
To 2035 · Planned
Operate & Scale
Production, regional supply and progressive expansion of the manufacturing base.
Production and support blocks
Production lines are the visible half. The support areas are what an inspector actually audits.
Feasibility
Technical and commercial studies precede any commitment.
Regulatory Approvals
Subject to the approvals required in the territory.
Financing
Phased investment aligned to each project stage.
Technical Partners
Delivered with qualified engineering partners.
Capital requirement
The complex is treated as a separate investment stream from trading, funded on its own terms and released in stages. The detailed capital allocation forms part of the investment memorandum and is shared with qualified strategic partners under confidentiality, not published here.
Strategic Partners & Investors
Detailed capital allocation, phasing and the full investment memorandum are released to qualified parties on request.
Planning targets, not commitments. These figures are strategic planning
targets. Actual outcomes depend on registration timelines, supplier credit, inventory
turnover, market acceptance, pricing, logistics, currency movement and compliance
restrictions. Nothing on this website is an offer of securities or an invitation
to invest.
Assurance
What a Partner Checks First
Before anyone talks about price, they ask who made it, whether it is registered here, and what happens when a batch is questioned. Those answers come before the catalogue.
Provenance
Every line names its manufacturer — Toei Shinyaku for KA21, MedVigilance for the rings.
Documentation
Specifications, certificates of analysis and stability data supplied with the quotation, not after the order.
Registration
Approved indications and device class differ by jurisdiction. Status is confirmed before a delivery date is given.
Labelling
Artwork, language and permitted claims adjusted per market. Nothing ships carrying an unapproved claim.
From enquiry to supply
Step 01
Enquiry
You tell us the market, volume and intended channel.
Step 02
Registration Check
We confirm what is approved where you are selling.
Step 03
Documentation
Specification, certificate of analysis and manufacturer statements issued.
Step 04
Sample & Artwork
Samples shipped, labelling adapted to the destination market.
Step 05
Supply
Order confirmed against agreed terms, shipped from the nearest office.
News & Insights
Notes From the Corridor
Short pieces on regulation, sourcing and supply into Central and South Asia, written for people who buy and register pharmaceuticals for a living.
Regulation · June 2026
Why registration status decides your delivery date
The gap between "available" and "importable" is where most first-time pharmaceutical orders fail. A short guide to checking approval before committing to a customer.
Sourcing · May 2026
Reading a certificate of analysis properly
What each section of a CoA actually tells you, which fields matter to a customs officer, and three checks worth doing before a batch leaves the manufacturer.
Diagnostics · April 2026
Point-of-care testing where the lab is far away
Why rapid diagnostics change clinical practice more in rural Central Asia than in well-served cities, and what that means for the devices you stock.
Frequently Asked
Questions We Get Before the First Order
Do you sell direct to consumers?
No. Nexara operates business to business — distributors, clinics, pharmacies and manufacturers. Consumer enquiries are pointed to a registered distributor where one exists.
Can you ship to a country not on the office list?
Sometimes, through one of the eight offices rather than directly. Tell us the destination and we will confirm whether it is workable before quoting.
What documentation comes with an order?
Specification sheet, certificate of analysis and manufacturer statements as standard. For devices, instructions for use and performance data as well — issued with the quotation, not after payment.
Are your supplements approved as medicines?
No. The King Agaricus KA21 line is sold as a food supplement and labelled accordingly in every market. Permitted wording differs by country and is set against local approval before shipment.
How long does a first order take?
It depends on the registration check in your market, not on stock. Some markets move in days, others need weeks of paperwork. We tell you which situation you are in before you commit.
Can I visit an office before ordering?
Yes, at any of the eight. Mention it in your enquiry and we will arrange a time with the local team.
Quality, Safety & Compliance
Quality. Compliance. Confidence.
Nexara operates as a distributor and trading partner. These are the functions through which product, documentation and safety obligations are managed.
Supplier Qualification
Suppliers are assessed and approved before any product is sourced through Nexara.
Regulatory Affairs
Requirements differ by territory; each market is treated on its own regulatory terms.
Quality Documentation
Product documentation is assembled per product and per market and shared with qualified partners.
Market Authorization
Products are supplied only where the applicable authorisation position has been confirmed.
Pharmacovigilance
A route exists for reporting safety events involving products supplied by Nexara.
Product Quality & Traceability
Complaints are handled through a defined route with traceability back to the supply chain.
No certification claim is made on this page. Nexara does not state or
imply FDA, WHO, GMP or ISO certification, or clinical proof, for any product or entity.
Where a specific certificate exists for a specific product and market, it is provided
directly to the partner concerned.
Partnerships
Partner With Nexara Pharma
We believe in the power of partnership to drive innovation, expand access and improve lives.
Manufacturers
Expand your reach into new markets.
Distributors
Build on a reliable healthcare portfolio.
Healthcare Institutions
Quality products for hospitals and clinics.
Technology Partners
Collaborate on digital and connected care.
OEM / Private Label
Custom development and private-label supply.
Investors
Participate in building long-term capacity.
Government & Institutional
Public health programmes and supply.
General Enquiries
Not sure which route fits? Contact us.
Send a partnership enquiry
Tell us the market, the volume and the channel. We reply from the office closest to you.
Do not send personal medical details. This form is for business
enquiries. For a suspected side effect or a product quality problem, contact your
healthcare professional first, then report it to us and to your national regulator.
Contact
Contact Us
We are here to answer your questions and explore new opportunities.
General enquiries
info@nexaralifecare.com
Chairman's office
jalal@nexaralifecare.com
Telephone
Canada +1 604 217 1225
Japan +81 45 550 7200
Head Office
31134 Edgehill Ave
Abbotsford, BC V2T 5J8
Canada
Medical Information
For medical information requests about our products.
Report a Safety Event
To report an adverse event or safety concern.
Product Quality Complaint
To report a concern about product quality.